

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 65737

**Title:** Successful treatment of acute relapse of chronic eosinophilic pneumonia with benralizumab and without corticosteroids: A case report

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05419820

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Israel

**Manuscript submission date:** 2021-04-14

**Reviewer chosen by:** Ze-Mao Gong

**Reviewer accepted review:** 2021-09-03 01:16

**Reviewer performed review:** 2021-09-04 17:12

**Review time:** 1 Day and 15 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
-------------------------------------	---

#### **SPECIFIC COMMENTS TO AUTHORS**

Thank you for inviting me to review the manuscript titled " Successful treatment of eosinophilic pneumonia with benralizumab: A case report". In this paper, the authors describe a case successfully treated with benralizumab for acute relapse and briefly discuss the issue. This provides us with new option for therapy osinophilic pneumoniawho suffer from side effects of corticosteroids or have contraindications for chronic corticosteroid treatment. However, in this study, case 2 and case 3: these patients were treated with prednisone and then with benralizumab. This is different from the successful treatment of chronic eosinophilic pneumonia with benarizumab alone. Case 1: Chest X-ray (September 6, 2020) showed pulmonary infiltration and absorption. It is necessary to provide lateral view to compare with the next chest X-ray.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 65737

**Title:** Successful treatment of acute relapse of chronic eosinophilic pneumonia with benralizumab and without corticosteroids: A case report

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05524527

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Israel

**Manuscript submission date:** 2021-04-14

**Reviewer chosen by:** Ze-Mao Gong

**Reviewer accepted review:** 2021-09-03 03:04

**Reviewer performed review:** 2021-09-06 01:33

**Review time:** 2 Days and 22 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

Dear editor, Thank you for inviting me to evaluate the article titled "Successful Treatment of Eosinophilic Pneumonia with Benralizumab: A Case Report". In the article, the author proposed that Benralizumab can serve as a good option for treatment of CEP. However, after a detailed evaluation, I personally think the structure of the article is not very clear and the content is not detailed enough. The specific problems are as follows: 1. Abstract-BACKGROUND mentioned: "Only 3 cases of successful treatment of CEP with Benralizumab alone without corticosteroids have been reported recently. We herein describe an additional similar case successfully treated With benralizumab for relapse and briefly discuss the issue.", but the following three cases are respectively introduced, and the first case is mainly introduced, while the following two cases are not accompanied by follow-up examination. I personally recommend that if there are already reported cases, there is no need to introduce them, and if there are not, they should be introduced in detail. 2. In the first case mainly introduced, the follow-up time was a little short, so the possibility of recurrence could not be fully understood. 3. In the first case, there was a lack of long-term follow-up of eosinophils, C-reactive protein, IgE, white blood cells and other results except the imaging results. 4. Lack of pathological results in diagnosis: for example, fibrobronchoscopy or lung biopsy. 5. The chest radiographs on January 12, 2021 were not displayed in front position. Therefore, I suggest that this article needs major revision before we consider whether to accept it. I hope my suggestion will be useful to you. Sincerely, Qiongdan Hu

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 65737

**Title:** Successful treatment of acute relapse of chronic eosinophilic pneumonia with benralizumab and without corticosteroids: A case report

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05386405

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Associate Chief Physician, Doctor, Instructor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Israel

**Manuscript submission date:** 2021-04-14

**Reviewer chosen by:** Ze-Mao Gong

**Reviewer accepted review:** 2021-09-02 15:10

**Reviewer performed review:** 2021-09-09 09:27

**Review time:** 6 Days and 18 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
-------------------------------------	---

#### **SPECIFIC COMMENTS TO AUTHORS**

Thank you for your submission. Your manuscript was an interesting read. But the manuscript is not well organized and does not follow a clear flow. Please see the following comments about how your data could be further clarified: 1. You reported three cases in the manuscript, however you didn't mention in the title and abstract. And it would be better that you would provide more details of diagnosis and treatment in the second case and the third case. 2. Is there the total eosinophils cell and differential cell count in Bronchoalveolar lavage fluid? 3. Can you explain why the recurrence of the first patients. 4. You mentioned that "benralizumab therapy seems to be preferred in patients with comorbidities that are expected to be aggravated under OCS treatment", then how to estimate the clinical effect of OCS treatment. 5. The text of the manuscript needs to be edited in terms of writing and grammar.